Cell-Free RNA (cfrna) Analysis Market Size & Share Analysis - Growth, Trends, & Forecasts (2025 - 2030)

The Cell-Free RNA (cfRNA) Analysis Market Report is Segmented by Type (Products and Services), by Technology (RNA Sequencing (RNA-Seq), Microarray Analysis, and Digital PCR), by Application (Oncology, Prenatal Screening, and Others), and by Geography North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

Cell-Free RNA (cfrna) Analysis Market Size & Share Analysis - Growth, Trends, & Forecasts (2025 - 2030)

Cell-Free RNA (cfRNA) Analysis Market Size

Cell-Free RNA (cfRNA) Analysis Market Summary
Study Period 2020 - 2030
Market Size (2025) USD 53.73 Million
Market Size (2030) USD 107.24 Million
CAGR (2025 - 2030) 14.82 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Cell-Free RNA (cfRNA) Analysis Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Cell-Free RNA (cfRNA) Analysis Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Cell-Free RNA (cfRNA) Analysis Market Analysis

The Cell-Free RNA Analysis Market size is estimated at USD 53.73 million in 2025, and is expected to reach USD 107.24 million by 2030, at a CAGR of 14.82% during the forecast period (2025-2030).

The cell-free RNA (cfRNA) analysis market refers to the commercial landscape encompassing the development, production, and utilization of technologies and services aimed at detecting, quantifying, and characterizing cfRNA molecules found in bodily fluids. The cfRNA analysis market is poised for growth due to technological advancements, increased interest in liquid biopsies, the rising burden of cancer, cardiovascular diseases, and neurological disorders, and ongoing research and development investments.

The increasing prevalence of diseases such as cancer and cardiovascular conditions drives demand for non-invasive diagnostic tools. For instance, according to an article published in the National Medical Journal of India in February 2024, it was observed that about 63 million people in India suffered from cardiovascular diseases in 2023, which was high compared to the last decade. In addition, cardiomyopathy, rheumatic heart disease, and right heart failure were the most prevalent categories of heart failure among the rural population in Chhattisgarh state of India. Thus, this market is driven by the increasing recognition of cfRNA as a valuable biomarker for various diseases, including cancer, cardiovascular diseases, and neurological disorders.

Furthermore, the shift towards minimally invasive diagnostic methods, such as liquid biopsies, is propelling the demand for cfRNA analysis. These methods allow for the detection of biomarkers without the need for invasive tissue biopsies.For instance, a study published in Human Genomics in October 2023 highlighted that liquid biopsy, the molecular analysis of body fluids, has emerged as a promising tool in cancer research, offering a more accessible assessment of patient health status than traditional tissue biopsies. Advancements in technology have enabled extensive genomic and transcriptomic analysis of DNA and RNA, especially in blood. Among the cell-free nucleic acids being studied, cell-free RNA (cfRNA) has garnered increasing attention for its tissue and cell-type specificity. Thus, such exploration of cfRNA in various diseases beyond cancer, such as cardiovascular diseases and neurological disorders, is expanding the market potential and applications of cfRNA analysis, thereby propelling to market growth.

Moreover, substantial investments in research and development by pharmaceutical and biotechnology firms drive advancements in cfRNA technologies. These advancements encompass the creation of novel assays and diagnostic instruments leveraging cfRNA. For example, in January 2022, Lucence, a precision oncology firm specializing in liquid biopsies for more precise cancer care, unveiled an enhanced version of its flagship LiquidHALLMARK liquid biopsy assay. This upgraded assay now incorporates cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling. Currently, the LiquidHALLMARK cfDNA and cfRNA assays are accessible to oncologists in the United States as laboratory-developed tests. Physicians actively employ these assays at centers designated by the National Cancer Institute (NCI) nationwide. Therefore, advancements in sequencing technologies and bioinformatics bolster the sensitivity and specificity of cfRNA analysis, paving the way for expanded growth opportunities in the market during the forecast period.

Hence, the studied market is posied to anticipated to grow over the forecast period owing to rising burden of cancer and other chronic diseases, growing preference for liquid biopsy, and ongoing innovations in the RNA technology field.

However, lack of skilled healthcare professionals and low market penetration may serve as an impediment for the studied market growth during the study period.

Cell-Free RNA (cfRNA) Analysis Industry Overview

The cell-free RNA (cfRNA) analysis market is generally considered fragmented. This fragmentation arises from the presence of numerous players, including small and medium-sized companies and larger established firms, each offering various technologies and services related to cfRNA analysis. Some of the market players holding substantial shares are as follows: QIAGEN, Bio-Rad Laboratories, Inc., Promega Corporation, Norgen Biotek Corp, Zymo Research Corporation, and several others. 

Cell-Free RNA (cfRNA) Analysis Market Leaders

  1. Norgen Biotek Corp

  2. QIAGEN

  3. Zymo Research Corporation

  4. Promega Corporation

  5. Bio-Rad Laboratories, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Cell-Free RNA (cfRNA) Analysis Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Cell-Free RNA (cfRNA) Analysis Market News

  • September 2024: PreAnalytiX GmbH, a joint venture between QIAGEN and BD (Becton, Dickinson, and Company), introduced the PAXgene Urine Liquid Biopsy Set. This set enables reliable analysis of cell-free DNA (cfDNA) from urine and is compatible with various molecular testing technologies such as qPCR, digital PCR, and next-generation sequencing (NGS). QIAGEN will commercialize the new set.
  • September 2024: Researchers at Cornell have developed machine-learning models that use cell-free molecular RNA remnants to diagnose difficult-to-differentiate pediatric inflammatory conditions. This diagnostic tool can accurately identify whether a patient has Kawasaki disease (KD), Multisystem Inflammatory Syndrome in Children (MIS-C), a viral infection, or a bacterial infection while also monitoring the patient's organ health.

Cell-Free RNA (cfRNA) Analysis Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cancer
    • 4.2.2 Growing Investment in Molecular Diagnostics
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Professionals
    • 4.3.2 Low Market Penetration
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Type
    • 5.1.1 Products
    • 5.1.2 Services
  • 5.2 By Technology Type
    • 5.2.1 RNA Sequencing (RNA-seq)
    • 5.2.2 Microarray Analysis
    • 5.2.3 Digital PCR
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Prenatal Screening
    • 5.3.3 Others
  • 5.4 By End User
    • 5.4.1 Hospitals and Clinics
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Norgen Biotek Corp
    • 6.1.2 QIAGEN
    • 6.1.3 Lucence Health Inc.
    • 6.1.4 NRICHDX
    • 6.1.5 Zymo Research Corporation
    • 6.1.6 CD Genomics
    • 6.1.7 STRECK
    • 6.1.8 Apostle Inc. (Apostle Sciences)
    • 6.1.9 Geneaid Biotech Ltd
    • 6.1.10 PlexBio Co., Ltd.
    • 6.1.11 Promega Corporation
    • 6.1.12 Bio-Rad Laboratories, Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Cell-Free RNA (cfRNA) Analysis Industry Segmentation

As per the scope of the report, cell-free RNA (cfRNA) analysis refers to the study and examination of RNA molecules that are found circulating freely in bodily fluids, such as blood, urine, and saliva, outside of cells. 

The cell-free RNA (cfRNA) market is segmented by type, technology, application, end user, and geography. By type, the market is segmented into products and services. By technology, the market is segmented into RNA sequencing (RNA-seq), microarray analysis, and digital PCR. By application, the market is segmented into oncology, prenatal screening, and others. By end user, the market is segmented into hospitals and clinics, diagnostic laboratories, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD) for the above segments.

By Type Products
Services
By Technology Type RNA Sequencing (RNA-seq)
Microarray Analysis
Digital PCR
By Application Oncology
Prenatal Screening
Others
By End User Hospitals and Clinics
Diagnostic Laboratories
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Cell-Free RNA (cfRNA) Analysis Market Research FAQs

How big is the Cell-Free RNA Analysis Market?

The Cell-Free RNA Analysis Market size is expected to reach USD 53.73 million in 2025 and grow at a CAGR of 14.82% to reach USD 107.24 million by 2030.

What is the current Cell-Free RNA Analysis Market size?

In 2025, the Cell-Free RNA Analysis Market size is expected to reach USD 53.73 million.

Who are the key players in Cell-Free RNA Analysis Market?

Norgen Biotek Corp, QIAGEN, Zymo Research Corporation, Promega Corporation and Bio-Rad Laboratories, Inc. are the major companies operating in the Cell-Free RNA Analysis Market.

Which is the fastest growing region in Cell-Free RNA Analysis Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Cell-Free RNA Analysis Market?

In 2025, the North America accounts for the largest market share in Cell-Free RNA Analysis Market.

What years does this Cell-Free RNA Analysis Market cover, and what was the market size in 2024?

In 2024, the Cell-Free RNA Analysis Market size was estimated at USD 45.77 million. The report covers the Cell-Free RNA Analysis Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Cell-Free RNA Analysis Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.